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Abstract 
Background: The targeted ERBB2 therapy, trastuzumab, has had a tremendous impact on management of patients 
with HER2+ breast cancer, leading to development and increased use of further HER2 targeted therapies. The major 
clinical side effect is cardiotoxicity but the mechanism is largely unknown. On the basis that gene expression is known 
to be altered in multiple models of heart failure, we examined differential gene expression of iPSC-derived cardiomyo-
cytes treated at day 11 with the ERBB2 targeted monoclonal antibody, trastuzumab for 48 h and the small molecule 
tyrosine kinase inhibitor of EGFR and ERBB2.
Results: Transcriptome sequencing was performed on four replicates from each group (48 h untreated, 48 h tras-
tuzumab and 48 h lapatinib) and differential gene expression analyses were performed on each treatment group 
relative to untreated cardiomyocytes. 517 and 1358 genes were differentially expressed, p < 0.05, respectively in 
cardiomyocytes treated with trastuzumab and lapatinib. Gene ontology analyses revealed in cardiomyocytes treated 
with trastuzumab, significant down-regulation of genes involved in small molecule metabolism (p = 3.22 × 10−9) 
and cholesterol (p = 0.01) and sterol (p = 0.03) processing. We next measured glucose uptake and lactate production 
in iPSC-derived cardiomyocytes 13 days post-plating, treated with trastuzumab up to 96 h. We observed significantly 
decreased glucose uptake from the media of iPSC-derived cardiomyocytes treated with trastuzumab as early as 24 h 
(p = 0.001) and consistently up to 96 h (p = 0.03).
Conclusions: Our study suggests dysregulation of cardiac gene expression and metabolism as key elements of 
ERBB2 signaling that could potentially be early biomarkers of cardiotoxicity.
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Background
As major advances are being made to understand the 
biology of the disease and optimize therapeutic benefit 
of various treatment strategies, side effects associated 
with those treatments must also be understood in order 
to minimize the dose/treatment limiting effects of such 
complications. One of the most impactful therapies for 
breast cancer is the humanized monoclonal antibody, 
trastuzumab (Herceptin®), which specifically recognizes 
the HER2 protein encoded by the ERBB2 gene. HER2 is 
part of a family of transmembrane receptors, is overex-
pressed in about 15–20% of invasive breast cancers, and 
is associated with aggressive biology and a natural history 
of shortened survival.
The original pivotal trial of trastuzumab in patients 
with HER2-positive metastatic breast cancer cre-
ated concern for the cardiac safety of patients receiving 
HER2 inhibitors after 27% of patients treated with con-
current anthracycline (when given at a cumulative dose 
of  >300  mg/m2)/cyclophosphamide/trastuzumab and 
13% of those treated with trastuzumab/paclitaxel experi-
enced some degree of cardiotoxicity [1]. Data from multi-
ple randomized adjuvant trials and observational studies 
suggest that the rate of discontinuation of trastuzumab 
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treatment ranges between 6 and 31%, mainly due to car-
diotoxicity [2–10]; and in patients aged  ≥65  years old, 
this figure increases to a notable and clinically relevant 
rate of 41% [11].
Trastuzumab is a monoclonal antibody that targets the 
protein HER2, but the mechanisms that account for tras-
tuzumab-mediated cardiotoxicity are largely unknown. 
The expert consensus statement from the American 
Society of Echocardiography and the European Associa-
tion of Cardiovascular imaging, classifies Trastuzumab 
as a Type II Cancer therapeutics-related cardiac dysfunc-
tion (CTRCD) agent because it does not directly cause 
cell damage in a cumulative dose-dependent fashion 
(unlike Type 1 CTCRD/anthracycline cardiotoxicity), and 
observed cardiac dysfunction is often reversible when 
treatment is discontinued [12, 13]. However classification 
of cardiotoxicity as Type I or II is confounded by the fact 
that such treatments are often given sequentially or con-
currently and that echocardiography may miss subtle car-
diac defects which do not change left ventricular ejection 
fraction (LVEF) measurement.
To some extent, these factors have been addressed in 
animal models, which allow single treatment with tras-
tuzumab and more invasive testing methods. ErbB2-
deficient conditional mutant adult mice were viable and 
displayed no overt phenotype, but physiological analysis 
revealed a phenotype consistent with dilated cardiomyo-
pathy [14, 15]. Isolated cardiomyocytes from conditional 
mutants were more susceptible to anthracycline toxicity, 
demonstrating that ErbB2 signaling in cardiomyocytes is 
requisite for the prevention of dilated cardiomyopathy 
(DCM) [14].
More recent pharmacological studies in both mouse 
and zebrafish suggest that the link between ErbB2 inhi-
bition and DCM is not directly linked to cardiomyocyte 
survival; rather that pharmacological inhibition of ErbB2/
erbb2 (without combination treatment with anthracy-
cline), can result in myofibril remodeling. Treatment of 
wild type mice with trastuzumab, resulted in impaired 
ventricular function, ultrastructural damage of heart tis-
sue (stretched appearance and reduced thickness of ven-
tricular cardiac myofibers), and differential expression of 
15 genes involved in adaptability to cardiac contractility, 
hemodynamic stress, DNA repair mechanisms, apop-
tosis, and mitochondrial function [16]. Taken together, 
mouse and zebrafish studies suggest that ErbB2/erbb2 
inhibition plays a role in cardiomyocyte survival follow-
ing anthracycline treatment, but also directly affects the 
structural organization of specific subpopulations of ven-
tricular myofibrils, even in the absence of anthracycline.
The limitations of these studies is their reliance on 
genetic models of erbb2 inhibition, or in the case of 
pharmacological experimentation, trastuzumab is a 
humanized monoclonal antibody and may not have the 
same efficacy in the mouse. Trastuzumab is not an option 
in zebrafish models, and the pharmacological inhibition 
in the literature [17–19] used PD168393, a compound 
that inhibits both EGFR and ERBB2 but is not used in the 
clinic.
Human induced pluripotent stem cell (hiPSC) derived 
cardiomyocytes are now a convenient option for the 
assessment cardiotoxicity of clinically relevant drugs in 
humans. On the basis that trastuzumab has been shown 
to alter the expression of genes essential for cardiac con-
tractility in a mouse model [16] and that different gene 
expression profiles in multiple models of heart failure 
are well known [20–25], we hypothesized that detailed 
examination of trastuzumab induced differential gene 
expression in human iPSC-derived cardiomyocytes could 
provide insight into the genes, pathways and potential 
biomarkers of trastuzumab induced cardiotoxicity.
Methods
Compounds
Trastuzumab, was received from Genentech (South San 
Francisco, CA) as a gift. Lapatinib Ditosylate was pur-
chased from LC Laboratories (Woburn, MA). We used 
100  µg/mL trastuzumab to represent a clinically rele-
vant dose. In studies of patients in which an initial dose 
of 4 mg/kg was followed by a weekly maintenance dose 
of 2  mg/kg, in combination with chemotherapy, the 
mean  ±  S.D. peak serum trastuzumab concentration 
at week 8 was 101.0  ±  30.6  µg/mL (n  =  115). Among 
patients receiving trastuzumab alone, mean ± S.D. peak 
concentration at week 8 was 95.6 ± 35.9 µg/mL [26]. We 
used 2 µM lapatinib Ditosylate based on previous obser-
vations [27].
Breast cancer cell culture
SKBR3, BT474, HCC1954, MDA-MB-453, HCC1569, 
and HCC1419 breast cancer cell lines were purchased 
from ATCC (Manassas, VA). SKBR3 and BT474 cell lines 
were maintained at in IMEM supplemented with 10% 
fetal bovine serum (FBS) and cultured at 37 °C, 5% CO2. 
HCC1954, HCC1569, and HCC1419 cells were cultured 
in RPMI with 10% FBS at 37 °C, 5% CO2. MDA-MB-453 
cells were cultured in L-15 with 10% FBS at 37  °C, no 
CO2. All cells passaged with 0.25% trypsin as needed.
Cardiomyocyte cell culture
iCell® cardiomyocytes were purchased from CELLular 
Dynamics International, CDI (Madison, WI) maintained 
according to the manufacturer’s recommended instruc-
tions. Cardiomyocytes were seeded with CDI’s plat-
ing media into fibronectin (5 µg/mL) coated wells at the 
appropriate density (2.4e5 cells per well of 12 well plate; 
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2e4 per well of 96 well plate. After 2  days, media was 
changed to CDI’s maintenance media and replaced every 
other day. Cells were maintained at 37 °C, 7% CO2 until 
10 days after plating at which time cells were treated with 
the appropriate drug for 48 h and endpoint assays (RNA 
extraction, viability/apoptosis) performed.
Western blot analysis
15 µg total cell lysates were prepared by briefly sonicat-
ing cell pellets in 1×  lysis buffer (Cell Signaling) sup-
plemented with a protease inhibitor mixture (Roche) 
and phosphatase inhibitors (PhosSTOP, Roche). Pro-
tein samples were resolved on Bolt 8% Bis–Tris Plus 
gels (ThermoFisher) and were electrophoretically trans-
ferred to a polyvinylidene difluoride membrane and 
blocked for 1  h at room temperature with 5% dry milk 
in TBST (50  mM  Tris, 150  mM  NaCl, 0.1% Tween, pH 
7.5). Blots were stained with antibodies against EGFR 
(D38B1), HER2/ERRB2 (D8F12), HER3/ERRB3(D22C5), 
and HER4/ERBB4 (111B2),and GAPDH (D16H11) pur-
chased from Cell Signaling Technology and used a dilu-
tion of 1:1000 in 5% dry milk in TBST for 1 h at 22 °C. For 
detection of PHLDA1 expression, blots were stained with 
1;1000 dilution of anti-PHLDA1 antibody (EPR6674, 
abcam®). For detection of PDK4 expression, blots were 
stained with 2  µg/mL dilution of anti-PDK4 (NBP1-
07049, Novus Biologicals). All blots were washed with 
three changes of TBST for a total of 45 min. Blots were 
then incubated in TBST buffer with 5% dry milk contain-
ing GAR-HRP (1:10,000, Cell Signaling Technology) for 
1 h at room temperature. After three washes with TBST, 
antigen–antibody complexes were detected with the ECL 
Plus chemiluminescent system (Amersham Biosciences) 
and visualized with film.
Transcriptome sequencing
RNA was extracted from breast cancer cell lines and 
iPSC-derived cardiomyocytes with the RNeasy mini-
kit (Qiagen). RNASeq libraries were prepared with the 
TruSeq v2 (Illumina Inc, San Diego, Ca), and sequenced 
by 101 base paired-end sequencing on an Illumina 
HiSeq  2000 (Illumina Inc, San Diego, Ca), mRNA as 
per the manufacturer’s instructions. Quality control, 
sequence alignment and gene expression counts were 
obtained using MAP-R seq workflow [28]. Transcriptome 
data is deposited in GEO, accession number GSE91383.
Quantitative PCR
Two-step quantitative reverse transcriptase-mediated 
real-time PCR (qPCR) was used to measure abundance 
of individual mRNAs. Equal aliquots of total RNA 
from samples were converted to cDNA with the High-
Capacity cDNA Archive kit (Applied Biosystems), and 
qPCR reactions were performed in triplicate with 10 ng 
of cDNA and the TaqMan Universal PCR master mix 
(Applied Biosystems). Primer/probe sets were purchased 
from Applied Biosystems. Amplification data were col-
lected with an Applied Biosystems ViiA7 detector and 
analyzed with ViiA7 v 1.2.4 software (Life Technolo-
gies). Data were normalized to the endogenous control 
POLR2A [29] and mRNA abundance was calculated 
using the ΔΔCT method [30].
Metabolic assays
Glucose was measured in cell culture supernatant by 
Amplex® Red Glucose/Glucose Oxidase Assay (Ther-
moFisher). Fluorescence was measured at 530/590  nm, 
and glucose concentration calculated via standard curve. 
Lactate was measured in cell culture supernatant using 
the Lactate Colorimetric/Fluorometric Kit (Biovision). 
Fluorescence was measured at 535/587 nm.
Apoptosis assay
Apoptosis was measured by caspase-3/7 activation with 
the ApoTox-Glo assay (Promega) as per the manufactur-
er’s instructions.
Statistical analyses
RNASeq statistical analyses were conducted with R ver-
sion 3.1.1. Transcriptome-wide differential expression 
analyses were undertaken via the edgeR package, version 
3.8.6. Cell lines and cardiomyocytes treated with trastu-
zumab or lapatinib were compared to untreated samples 
(four replicates each group). Genes with less than two 
samples expressed at two counts-per-million or greater 
were considered beneath the threshold of detection and 
filtered from all analyses. To correct for multiple testing, 
Benjamini and Hochberg’s FDR method was applied and 
a threshold of q < 0.05 was considered significant.
Gene enrichment analyses were performed with the 
Gene Ontology (GO) Consortium database [31, 32] in 
each cell type following ERBB2 inhibition. For each tran-
scriptome, we took those genes differentially expressed, 
p  <  0.05 and searched for enrichment of gene ontology 
categories by biological process.
Significance of qPCR fold change, glucose uptake, 
lactate production and apoptosis following treatment 
with trastuzumab or lapatinib was analyzed by T test in 
Graphpad Prism.
Results
ERBB expression in iPSC‑derived cardiomyocytes 
and cancer cell lines overexpressing ERBB2
To put into context, ERBB2 expression levels in cancer cell 
lines overexpressing ERBB2 and iPSC-derived cardiomyo-
cytes, we examined RNA and protein expression levels of 
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the ERBB family. Gene expression of all members of the 
ERBB family of tyrosine kinase receptors was detected 
in cardiomyocytes and cancer cell lines overexpressing 
ERBB2 (Fig. 1). As expected, ERBB2 expression was sig-
nificantly higher in the ERBB2-overexpressing cancer cell 
lines (mean 12.9 log2 counts per million), but ERBB2 was 
also expressed in iPSC-derived cardiomyocytes, 8.96 log2 
counts per million. ERBB2 gene expression is shown sepa-
rately for each of the six cancer cell lines in Fig. 1.
Protein levels of each ERBB family member in iPSC-
derived cardiomyocytes are shown in Fig. 2. Using 15 µg 
of cell lysate, only ERBB2 and ERBB4 were detected at 
the protein level in iPSC-derived cardiomyocytes. The 
lack of EGFR expression in the iPSC-derived cardiomyo-
cytes suggests that the action of lapatinib which targets 
EGFR and ERBB2 is not through inhibition of EGFR, 
but either ERBB2 or ERBB2 in combination with any 
off-target effects. ERBB2 protein was down-regulated by 
trastuzumab in iPSC-derived cardiomyocytes, but not 
by lapatinib. Trastuzumab did not down-regulate ERBB2 
protein expression in ERBB2 overexpressing cancer cell 
lines (Fig. 3).
Trastuzumab induced significant differential gene 
expression in iPSC‑derived cardiomyocytes
517 genes were differentially expressed in iPSC-derived 
cardiomyocytes treated with trastuzumab at p < 0.05, of 
which 137 showed fold change >1.5 (49 down-regulated, 
88 up-regulated). Only one gene, IL31RA remained sig-
nificant following correction for multiple testing, fold 
change 3.85, p = 1.56 × 10−6, q = 0.025. Full differential 
expression results are shown in Additional file 1: Table S1.
Overlap of trastuzumab induced differentially expressed 
genes is relatively small between ERBB2‑overexpressing 
cancer cell lines and iPSC‑derived cardiomyocytes
We observed a high degree of overlap in the genes 
expressed in iPSC-derived cardiomyocytes and 
Fig. 1 RNA expression of ERBB family in iPSC-derived cardiomyo-
cytes and cancer cell lines overexpressing ERBB2. At the level of RNA, 
ERBB2-overexpressing cancer cell lines express higher levels of ERBB2 
by ~1–5 orders of magnitude relative to iPSC-derived cardiomyo-
cytes. iPSC-derived cardiomyocytes expressed moderate levels of 
ERBB4, and low levels of EGFR and ERBB3
Fig. 2 Protein expression of ERBB family in iPSC-derived cardiomyo-
cytes. Western blot of 15 µg of total cell lysate of iPSC-derived cardio-
myocytes stained for members of the ERBB family. GAPDH was used 
as loading control. ERBB2 and ERBB4 are expressed in iPSC-derived 
cardiomyocytes at the level of protein. We did not observe protein 
expression of EGFR and ERBB4
Fig. 3 Trastuzumab down-regulates ERBB2 in iPSC-derived cardio-
myocytes, but not in ERBB2 overexpressing cancer cell lines. a West-
ern blot of 15 µg of total cell lysate stained for ERBB2 in MDA-MB-231 
(non-ERBB2 overexpressing breast cancer cell line negative control), 
and iPSC-cardiomyocytes treated with trastuzumab and lapatinib. 
ERBB2 expression was down-regulated by trastuzumab but not by 
lapatinib. b ERBB2 expression was not altered by trastuzumab in the 
ERBB2 overexpressing cancer cell lines, BT474 and SKBR3
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ERBB2-overexpressing cancer cell lines. Of the 14,946 
genes expressed above background in the cancer cell 
lines, 11,466 (77%) were also expressed above back-
ground in the iPSC cardiomyocytes (Additional file  2: 
Figure S1A). As further validation of changes in gene 
expression mediated by ERBB2 inhibition, we next 
assessed the overlap of trastuzumab induced differen-
tial gene expression between the ERBB2-overexpress-
ing cancer cell lines and iPSC-derived cardiomyocytes. 
76/11,466 (0.66%) genes expressed in both cell types were 
differentially expressed, p < 0.05, (Additional file 2: Figure 
S1B). 76 genes were differentially expressed, p < 0.05 in 
both cancer cell lines and iPSC-derived cardiomyocytes 
following treatment with trastuzumab (Table  1). 63/76 
genes showed fold changes in the same direction in both 
cancer cell lines and iPSC-derived cardiomyocytes.
Validation of trastuzumab induced differentially expressed 
genes in iPSC‑derived cardiomyocytes by additional ERBB2 
targeted compounds
We also performed transcriptome sequencing on iPSC-
derived cardiomyocytes following 48  h treatment with 
the small molecule tyrosine kinase inhibitor, lapatinib, 
and examined differential gene expression of treated ver-
sus untreated cells. We observed a total of 1358 genes 
that were differentially expressed following treatment 
with lapatinib at p  <  0.05, of which 533 showed fold 
change >1.5 (271 up-regulated and 262 down-regulated). 
75 genes remained significant q  <  0.05 after correction 
for multiple testing, the most significant of which was 
PHLDA1, p = 8.89 × 10−9, q = 0.0001, fold change 0.29. 
Differential gene expression data for all genes following 
treatment with lapatinib is shown in Additional file  3: 
Table S2.
38/137 (28%) of genes that were differentially expressed 
in iPSC cardiomyocytes following treatment with tras-
tuzumab, were also differentially expressed following 
treatment with lapatinib, p < 0.05 and fold change >1.5, 
(Table  2), including the most significantly differentially 
expressed genes from both drugs, IL31RA from trastu-
zumab and PHLDA1 from lapatinib. 93% of genes that 
were differentially expressed following treatment with 
lapatinib were not significantly changed by treatment 
with trastuzumab, demonstrating the wider range of 
effect of the tyrosine kinase inhibitor relative to mono-
clonal antibody.
To validate the differentially expressed genes identi-
fied by transcriptome sequencing, we selected genes with 
fold changes  >1.5, p  <  0.05, following treatment with 
both trastuzumab and lapatinib: EGR1, PHLDA1, RGS4, 
SLC6A6 for qPCR in RNA extracted from two separate 
batches of iPSC-derived cardiomyocytes (Fig. 4). To fur-
ther evaluate ERBB2 inhibition of these genes, we also 
treated cells from a new batch of iPSC-derived cardio-
myocytes with additional ERBB2 inhibitors, neratinib, 
afatinib and poziotinib. PHLDA1 and SLC6A6 were sig-
nificantly down-regulated by all inhibitors (Additional 
file 4: Figure S2). We also confirmed down-regulation of 
PHLDA1 at the level of protein expression by Western 
blot, (Fig. 5).
ERBB2 inhibition down‑regulates genes involved 
in metabolism in iPSC‑derived cardiomyocytes 
and ERBB2‑overexpressing cancer cell lines
We used gene ontology (GO) [31, 32] to perform gene 
enrichment analyses in each cell type following ERBB2 
inhibition. For each transcriptome, we took those genes 
differentially expressed at p  <  0.05 and searched for 
enrichment of gene ontology categories by biological 
process. Following Bonferroni correction of each GO 
term, a total of 272 GO terms were associated at p < 0.05 
with differentially expressed genes in ERBB2-overex-
pressing cancer cell lines treated with trastuzumab. Not 
surprisingly, the majority of these terms related to cell 
cycle processes, with mitotic cell cycle, GO:0000278 
being the most significant, p = 2.62 × 10−42 (Additional 
file 5: Table S3). We observed a similar trend in cardio-
myocytes treated with lapatinib. 88 GO terms were asso-
ciated at p < 0.05 with differentially expressed genes, the 
most significant terms being, mitotic nuclear division, 
GO:0007067, p = 1.09 × 10−15 and mitotic cell cycle pro-
cess, GO:1903047, p  =  1.68  ×  10−14 (Additional file  6: 
Table S4).
However, in cardiomyocytes treated with trastu-
zumab, following Bonferroni correction, only 20 GO 
terms were associated at p  <  0.05 with the differen-
tially expressed genes, all of which related to metabo-
lism. The most significant GO term was small molecule 
metabolic process, p = 3.22 × 10−9 (which included the 
taurine transporter, SLC6A6, already shown to be sig-
nificantly down-regulated by multiple ERBB2 inhibi-
tors in qPCR validation) and multiple terms relating to 
cholesterol processing were associated [cholesterol bio-
synthetic process (GO:0006695), cholesterol metabolic 
process (GO:0008203) and sterol biosynthetic process 
(GO:0016126) (Additional file  7: Table S5)]. Post-hoc 
examination of the differentially expressed genes within 
these categories identified the same set of recurring 
genes (LDLR, SREBF1, ABCA1, CLN6, MSMO1, INSIG1, 
NSDHL, DHCR24, DHCR7, IDI2, FDPS, IDI1) detailed 
in Additional file 8: Table S6, 11/12 of which were down-
regulated by trastuzumab.
The same GO terms relating to small molecule meta-
bolic process and cholesterol metabolic process in cardio-
myocytes treated with trastuzumab, were also significant 
in cardiomyocytes treated with lapatinib (GO:0044281, 
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Table 1 76 genes were differentially expressed in both ERBB2-overexpressing cancer cell lines and iPSC-derived cardio-
myocytes, following treatment with trastuzumab, p < 0.05
Gene ERBB2‑overexpressing cancer cell lines iPSC‑derived cardiomyocytes
logCPM FC p value logCPM FC p value
DDX60 4.37 1.31 2.32E−04 4.42 1.68 0.001
GABRP 3.10 1.43 0.032 0.51 2.46 0.001
DHCR24 9.72 0.82 0.001 5.84 0.68 0.002
DHCR7 7.60 0.75 1.06E−04 4.53 0.70 0.002
BMF 5.23 1.49 1.49E−04 6.86 1.48 0.002
PTPRE 2.23 1.27 0.036 3.21 1.71 0.002
INSIG1 6.79 0.72 9.13E−05 4.21 0.72 0.003
TYMS 5.54 0.81 0.030 6.02 0.67 0.003
SCD 10.80 0.59 0.000 6.18 0.69 0.004
ZNF90 1.88 0.66 0.039 2.21 0.70 0.006
SEMA6C 3.01 1.80 0.001 6.18 1.36 0.006
PRSS23 6.64 1.22 6.12E−04 4.95 1.38 0.006
CDK1 7.12 0.80 0.023 5.25 0.70 0.007
REPS2 4.96 1.15 0.021 4.96 1.46 0.007
LDLR 7.78 0.81 1.63E−04 5.84 0.66 0.007
YARS 7.38 0.89 0.027 6.97 0.79 0.007
MSMO1 6.95 0.80 0.002 5.51 0.72 0.008
UBE2T 5.57 0.87 0.023 4.74 0.71 0.012
SEPP1 5.87 1.32 0.006 5.56 1.29 0.015
SREBF1 9.23 0.85 0.008 4.06 0.69 0.015
CLU 8.72 1.23 9.44E−04 5.81 1.37 0.016
TOMM40 6.91 0.84 0.002 5.37 0.74 0.017
ABCA1 2.46 1.43 0.003 5.32 1.48 0.017
NSDHL 5.41 0.84 0.004 4.22 0.77 0.018
KIF18B 5.33 0.78 0.014 3.52 0.70 0.018
ERO1LB 4.05 1.21 0.025 3.76 1.35 0.019
NEIL3 4.17 0.80 0.036 1.84 0.66 0.019
HIST2H2BE 5.09 1.20 0.019 6.96 1.34 0.019
TUBA1B 7.79 0.81 0.015 7.92 0.75 0.021
FDPS 7.37 0.80 0.001 5.83 0.82 0.022
ERV3-1 3.53 1.18 0.027 3.95 1.38 0.023
ACAT2 5.76 0.72 0.002 4.80 0.74 0.024
PPL 6.33 1.11 0.048 4.97 1.38 0.024
NBR1 7.15 1.12 0.026 7.24 1.25 0.027
PDSS1 3.74 0.75 0.007 2.24 0.72 0.027
CCDC28A 3.39 1.33 6.92E−04 2.38 1.33 0.027
ETNK1 6.47 1.12 0.010 5.65 1.25 0.027
SNAP23 6.44 1.10 0.050 6.19 1.23 0.027
TUBG1 5.00 0.84 0.016 5.01 0.81 0.028
RRS1 5.59 0.85 0.004 3.69 0.72 0.029
MATN2 5.79 1.39 8.99E−04 5.89 1.28 0.032
NCAPH 5.88 0.76 0.007 3.31 0.69 0.032
AKAP3 0.90 1.44 0.033 1.59 1.41 0.032
MPV17L2 3.69 0.81 0.001 4.46 0.77 0.032
PTGES2 6.47 0.89 0.023 5.85 0.74 0.034
WDR4 4.54 0.79 0.005 2.11 0.76 0.036
TXNIP 7.50 1.38 5.31E−04 4.36 1.30 0.037
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p = 4.94 × 10−4; GO:0008203, p = 3.90 × 10−3 respec-
tively) and ERBB2-overexpressing cells treated with tras-
tuzumab (GO:0044281, p =  1.23 ×  10−10; GO:0008203, 
p = 1.35 × 10−3) (Table 3).
Trastuzumab induced ERBB2 inhibition down‑regulates 
glucose uptake in iPSC‑derived cardiomyocytes
Following the link to trastuzumab induced differ-
ential expression of genes involved in metabolism, 
which included up-regulation (confirmed at the level 
of protein, Fig.  5), of PDK4, an inhibitor of the pyru-
vate dehydrogenase complex and hence glycolysis, 
and down-regulation of multiple genes located in the 
mitochondria, perhaps reflecting a reduction in oxida-
tive phosphorylation, (ALDH1L2, SLC27A3, SLC25A25, 
SLC25A5, SLC25A6 and UCP2, fold change and p 
values in Additional file  1: Table S1), we next exam-
ined the effect of trastuzumab on glycolysis. Follow-
ing treatment with trastuzumab, we measured glucose 
uptake (based on measuring the amount of glucose in 
the media) up to 96  h. Cardiomyocytes treated with 
trastuzumab showed significantly higher amounts of 
glucose in the media (hence lower glucose uptake) as 
early as 24 h post-treatment (p =  0.001), and this dif-
ference remained significant up to 96 h post-treatment 
(p = 0.03), (Fig. 6).
63/76 genes showed fold changes in the same direction. 13 genes with FC in the opposite direction between cancer cell lines and iPSC-derived cardiomyocytes are 
listed at the bottom of the table in italics. All genes are ordered by p values in cardiomyocytes
Differential gene expression analyses were performed in six cancer cell lines overexpressing ERBB2 (BT474, HCC1419, HCC1569, HCC1954, MDAMB453 and SKBR3) and 
in iPSC-derived cardiomyocytes following treatment with trastuzumab
iPSC induced pluripotent stem cell, logCPM log 2 counts per million, FC fold change
Table 1 continued
Gene ERBB2‑overexpressing cancer cell lines iPSC‑derived cardiomyocytes
logCPM FC p value logCPM FC p value
TOP3A 6.15 0.87 0.007 4.74 0.84 0.038
PDK4 1.08 2.20 1.80E−05 2.77 1.43 0.039
BCAS3 4.46 1.21 0.009 4.42 1.25 0.039
RRM2 8.39 0.76 0.014 5.27 0.77 0.039
CHCHD3 6.22 0.87 0.031 6.56 0.82 0.039
MBNL2 6.95 1.12 0.023 5.89 1.31 0.040
RAB17 5.09 1.17 0.039 2.04 1.50 0.040
BIRC5 6.58 0.79 0.023 4.81 0.70 0.040
PGAM5 6.54 0.82 3.46E−04 5.09 0.80 0.040
IDI1 7.37 0.82 0.003 5.76 0.82 0.043
FADS2 7.15 0.76 0.013 6.90 0.81 0.046
RNASEH2A 5.57 0.85 0.033 3.52 0.69 0.046
NFASC 4.95 1.55 0.005 0.68 1.58 0.048
PAK1IP1 5.00 0.89 0.048 2.88 0.81 0.049
DHFR 6.93 0.86 0.018 6.46 0.82 0.049
FHL1 3.30 1.49 0.041 7.24 1.21 0.050
PRODH 7.11 1.24 0.005 2.43 0.59 0.003
KCNQ5 0.32 0.57 0.019 4.02 1.54 0.006
PIM1 4.28 1.25 0.005 3.68 0.72 0.006
MAP6D1 3.06 1.17 0.038 2.05 0.70 0.011
TLL1 −0.08 0.64 0.049 2.36 1.76 0.013
DYNC1LI1 5.67 0.89 0.022 7.96 1.28 0.015
MXRA5 6.22 0.83 0.019 1.33 1.90 0.015
RILPL2 3.16 1.27 0.012 2.11 0.72 0.023
RPL18A 8.66 1.11 0.028 5.97 0.77 0.032
NAGLU 4.69 1.17 0.023 3.64 0.76 0.034
RNF39 3.05 1.28 0.046 1.04 0.70 0.039
RPS18 9.84 1.11 0.041 8.29 0.76 0.040
ARHGAP18 4.99 1.11 0.040 0.74 0.67 0.048
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Trastuzumab induced ERBB2 inhibition did not alter lactate 
production in iPSC‑derived cardiomyocytes
Pyruvate can be converted to either lactate in the glyco-
lytic pathway, or to acetyl co-enzyme A via the pyruvate 
dehydrogenase complex, linking glycolysis to the tricar-
boxylic (TCA) cycle and fatty acid synthesis. Our differ-
ential expression data showed up-regulation of PDK4, an 
inhibitor of the pyruvate dehydrogenase complex, sug-
gesting that trastuzumab could increase lactate produc-
tion. We measured lactate production in cardiomyocyte 
media following 48 h treatment with trastuzumab. How-
ever, we did not observe any change in lactate produc-
tion, despite significantly lower glucose uptake (Fig. 7).
Discussion
Current standard of care requires patients to receive tras-
tuzumab for 12 months during which time they are mon-
itored by echocardiography. Those patients experiencing 
significant declines in LVEF are treated with standard 
heart failure medications such as beta blockers or ACE 
inhibitors, and if LVEF does not recover, trastuzumab 
may be withheld. We hypothesized that identifying early 
changes in gene expression mediated by trastuzumab 
could potentially identify novel therapeutic targets for 
prevention of cardiac side-effects or potential biomark-
ers of drug-induced cardiotoxicity. We used commer-
cially available, human iPSC-derived cardiomyocytes 
from a “healthy” female individual, treated with clini-
cally relevant ERBB2 targeted therapies, trastuzumab and 
lapatinib to identify early therapy induced changes. We 
identified two groups of genes that may be relevant in the 
management of cardiotoxicity.
Firstly, the small group of significantly differentially 
expressed genes in iPSC-derived cardiomyocytes treated 
with trastuzumab and lapatinib, related to cardiac dys-
function and ischemic injury. EGR1 and PHLDA1, both 
down-regulated in our experiments, are significantly 
upregulated in ischemic preconditioning [17], suggesting 
perhaps that prevention of this change in gene expression 
could be protective against ERBB2 therapy related car-
diotoxicity. Absence of regulator of G-protein signaling 4 
(RGS4) predisposes to atrial fibrillation and is associated 
with abnormal calcium handling [33] and activation of 
RGS4 mediates the cardioprotective effects of natriuretic 
peptides in the heart [34], of which natriuretic peptide 
A, NPPA, was also significantly down-regulated by tras-
tuzumab and lapatinib. Solute carrier family 6, member 
6 (SLC6A6), is a transporter of taurine, an endogenous 
sulfur-containing beta-amino acid, associated with cal-
cium handling, protection against ischemia–reperfusion 
injury, heart failure ischemic heart disease, and diabetic 
cardiomyopathy [35]. Slc6a6 knock out mouse mod-
els demonstrate a phenotype of dilated cardiomyopathy 
with cardiac atrophy [36], lower fasting blood glucose, 
acceleration of glycolysis in skeletal muscle and suscep-
tibility to development of obesity when placed on a high 
fat diet [37]. Taken together, our findings of trastuzumab 
Table 2 Differentially expressed genes in  cardiomyocytes 
following ERBB2 inhibition
Overlap of trastuzumab and lapatinib differentially expressed genes in 
cardiomyocytes, fold change >1.5, p < 0.05
iPSC induced pluripotent stem cell, FC fold change






FC p value FC p value
PHLDA1 4.366 0.53 0.003 0.29 8.89E−09
SLC6A6 3.051 0.53 0.006 0.27 2.35E−08
RGS4 1.850 0.66 0.022 0.41 1.15E−06
LDLR 5.843 0.66 0.007 0.48 1.98E−06
RP11-290L1.3 2.017 0.44 0.004 0.26 3.09E−06
FSTL5 1.461 2.26 2.25576E−05 2.23 2.93E−05
EGR1 3.271 0.40 6.21035E−05 0.39 4.71E−05
KRT6A −1.435 0.00 1.51E−04 0.00 1.42E−04
STK32A 1.068 1.97 6.48E−04 2.08 2.05E−04
PRRT4 2.336 1.72 2.62E−04 1.68 4.71E−04
FAM71F2 0.724 1.91 0.007 2.22 0.001
ZNF483 1.654 1.76 0.018 2.22 0.001
ACRC 0.475 1.65 0.025 2.09 0.001
RP11-285F7.2 0.797 1.66 0.020 2.03 0.001
LINC00842 3.506 1.64 0.001 1.61 0.002
RP3-434O14.8 0.954 2.14 0.001 1.97 0.002
NFASC 0.677 1.58 0.048 1.99 0.002
PMCH 0.823 0.64 0.047 0.51 0.003
CAV3 0.797 1.58 0.027 1.81 0.004
AL132989.1 0.577 2.04 0.012 2.18 0.006
SDC1 1.833 0.62 0.013 0.60 0.007
SLC28A1 1.089 1.96 0.028 2.25 0.008
KIAA1107 2.568 1.54 0.028 1.68 0.008
PLK3 0.683 0.55 0.006 0.56 0.009
SLC7A7 1.628 2.00 1.39564E−05 1.51 0.011
GRM8 0.678 1.92 0.011 1.89 0.012
NPY4R 0.487 1.85 0.032 2.06 0.012
FAM110A 1.255 0.64 0.011 0.66 0.016
GFAP 1.856 0.62 0.006 0.66 0.017
APBB1IP 0.323 2.46 0.003 2.06 0.019
IL31RA 0.956 3.85 1.56156E−06 1.94 0.020
RPP25 2.028 0.65 0.045 0.61 0.020
AC007036.5 2.769 1.64 0.023 1.66 0.020
LINC00327 0.750 1.59 0.009 1.51 0.021
PKN3 2.451 0.65 0.024 0.66 0.024
MTFP1 2.980 0.64 0.037 0.62 0.026
PROM1 1.535 1.69 0.010 1.55 0.031
ATF4P3 1.473 0.58 0.007 0.66 0.038
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induced down-regulation of SLC6A6 in human iPSC-
derived cardiomyocytes, and the reported phenotypes of 
dilated cardiomyopathy and altered metabolism in Slc6a6 
knock-out mice provide a potential mechanism towards 
trastuzumab related cardiotoxicity.
The second group of trastuzumab regulated genes in 
our iPSC-derived cardiomyocyte model involved metab-
olism. Enrichment analyses identified gene ontology cate-
gories: small molecule metabolism, cholesterol and sterol 
metabolism and cholesterol and sterol biosynthesis, and 
expression of the majority of genes in these categories 
was down-regulated across iPSC-derived cardiomyo-
cytes treated with trastuzumab and lapatinib and also 
in cancer cell lines overexpressing ERBB2. In the case of 
iPSC-derived cardiomyocytes treated with trastuzumab, 
specifically, only metabolic gene ontology categories were 
significantly enriched. This is in contrast to ERBB2-over-
expressing cancer cell lines treated with trastuzumab, in 
which the most significantly enriched categories related 
to cell cycle. We note at this point, a similar pattern in 
trastuzumab-induced down-regulation of ERBB2 protein 
levels between cancer cells and cardiomyocytes. In our 
Fig. 4 qPCR validation of differential expression of RGS4, EGR1, SLC6A6 and PHLDA1 by trastuzumab and lapatinib in iPSC-derived cardiomyocytes. 
Standard deviation (SD) calculated from three replicates. Down-regulation of: a RGS4, b SLC6A6, c EGR1 and d PHLDA1 by trastuzumab and lapatinib 
was confirmed by qPCR. Student’s T-test, unequal values, p < 0.05*; p < 0.01**
Fig. 5 Trastuzumab and lapatinib induced down-regulation of 
PHLDA1 protein expression and up-regulation of PDK4 protein 
expression. Western blot of 15 μg of total cell lysate of iPSC-derived 
cardiomyocytes stained for PHLDA1 and PDK4
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data, and that of others, ERBB2 was down-regulated by 
trastuzumab in cardiomyocytes [38] but not in ERBB2 
overexpressing cancer cell lines [39]. This is not sur-
prising given the different mechanisms of inhibition of 
ERBB2 signaling and trafficking between cancer cells and 
cardiomyocytes [40, 41], in which treatment results in 
reduced proliferation and induction of apoptosis in can-
cer cell lines [42, 43] and reduced contractility without 
apoptosis in cardiomyocytes, (Additional file  9: Figure 
S3) [12, 44].
Regards enrichment of differential expression of 
metabolism related genes, the largest metabolic category, 
was small molecule metabolism (N  =  98 genes), which 
included the taurine transporter, SLC6A6, key enzymes in 
glucose metabolism (PDK4 and GLA) and mitochondrial 
transporters (SLC27A3, SLC25A25, SLC25A5, SLC25A6). 
Due to the high energy demand of the heart, cardiac 
metabolism is highly flexible. In the ‘normal/healthy’ 
heart, mitochondria are primarily fueled by the metabo-
lites of fatty acids and carbohydrates, but under chronic 
pathological conditions, the heart has the capacity to 
remodel metabolic pathways, and subsequently, myo-
cardial energetics and contractile function [45], although 
these data relate mostly to reprogramming in response 
Table 3 Gene ontology enrichment analysis
Differentially expressed genes following treatment with trastuzumab or lapatinib were assessed for enrichment in gene ontology categories of biological process. 
517 genes were significantly differentially expressed in iPSC-derived cardiomyocytes following treatment with trastuzumab. 428/517 genes were recognized within 
the Gene Ontology (GO) Consortium reference dataset of 20,814 genes and analyzed for enrichment. Similarly, of 1358 differentially expressed genes following 
treatment of iPSC-derived cardiomyocytes with lapatinib, 1077 were recognized in the GO reference set and analyzed for enrichment. Of 2272 differentially expressed 
genes following treatment with trastuzumab in ERBB2-overexpressing cancer cell lines, 2097 were recognized in the GO reference set and analyzed for enrichment. 















iPSC cardiomycytes treated with trastuzumab
 Genes uploaded to 
enrichment analysis
428/517 428/517 428/517 428/517 428/517
 Uploaded genes in 
category
98 12 NS 8 8
 Expected genes in 
category
45.92 2.24 0.78 0.88
 Category fold enrich-
ment
2.13 >5 >5 >5
 p value (adjusted) 3.22E−09 0.030 0.013 0.031
iPSC cardiomycoytes treated with lapatinib
 Genes uploaded to 
enrichment analysis
1077/1358 1077/1358 1077/1358 1077/1358 1077/1358
 Uploaded genes in 
category
173 21 21 12 12
 Expected genes in 
category
115.54 5.64 6.31 1.97 2.22
 Category fold enrich-
ment
1.5 3.72 3.33 >5 >5
 p value (adjusted) 4.94E−04 0.004 0.022 0.009 0.030
ERBB2-overexpressing cancer cell lines treated with trastuzumab
 Genes uploaded to 
enrichment analysis
2097/2272 2097/2272 2097/2272 2097/2272 2097/2272
 Uploaded genes in 
category
340 32 32 22 22
 Expected genes in 
category
224.97 10.98 12.29 3.83 4.33
 Category fold enrich-
ment
1.51 2.91 2.6 >5 >5
 p value (adjusted) 1.23E−10 0.001 0.014 1.12E−06 1.06E−05
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to pathological hypertrophy, characterized by increased 
reliance on glucose metabolism and decreased fatty acid 
oxidation. The effect of trastuzumab, on glucose uptake 
in iPSC-derived cardiomyocytes suggests a different met-
abolic change to that observed in cardiac hypertrophy. 
We observed significantly more glucose in the media of 
iPSC-derived cardiomyocytes treated with trastuzumab 
within 24  h and constantly up to 96  h, indicative of a 
lower uptake of glucose as a result of trastuzumab, with 
negligible change in lactate. These observations are in 
line with studies of “lipid status” responsiveness, whereby 
up-regulation of PDK4, facilitates fatty acid oxidation by 
“sparing” pyruvate for oxaloacetate formation [46, 47]. In 
heart and skeletal muscle, increased anaplerotic entry of 
pyruvate into the TCA cycle as oxaloacetate facilitates 
entry of acetyl co-A derived from fatty acid β-oxidation 
into the TCA cycle through increased citrate formation, 
which in turn, acts as a sensor of fatty acid abundance 
and suppresses glucose uptake [46].
Observations of trastuzumab induced changes in 
metabolism are clinically relevant in light of poten-
tial metabolic therapies for heart failure. For example, 
dichloracetate (DCA), a drug shown to improve cardiac 
function in right ventricular hypertrophy and failure 
[48, 49], increases pyruvate dehydrogenase activity by 
inhibiting PDK, and perhaps could potentially reverse 
the effects of trastuzumab. The efficacy of DCA treat-
ment has also been demonstrated in functional recovery 
during reperfusion in multiple animal models [50–53]. 
Lewandowski and White [52] demonstrated that coun-
teracting depressed pyruvate oxidation enhanced con-
tractile recovery in post-ischemic rabbit hearts. Of note, 
two of the most consistently down-regulated genes fol-
lowing ERBB2 inhibition, were EGR1 and PHLDA1, 
which have also been shown to be up-regulated in mod-
els of ischemic preconditioning [17].
In summary our transcriptome based approach of tras-
tuzumab induced changes in iPSC-derived cardiomyo-
cytes identified significant down-regulation of expression 
of genes associated with ischemic preconditioning and 
cardiac dysfunction, and more significantly with genes 
involved in metabolism. The main caveats of the study 
are the reliance on an in  vitro model of iPSC-derived 
cardiomyocytes which may not reflect fully mature dif-
ferentiated human cardiomyocytes and does not address 
potential immune response, and lack of functional data. 
However, our reported changes of trastuzumab mediated 
differential gene expression in cardiomyocytes were vali-
dated with additional ERBB2 targeted compounds and 
we also observed considerable overlap in ERBB2-over-
expressing cancer cell lines which we interpret as strong 
evidence that ERBB2 inhibition is responsible for our 
reported changes in gene expression. We acknowledge, it 
is not proven that these specific genes functionally con-
tribute to dysregulation of glycolysis in iPSC-derived car-
diomyocytes, but we note that knock out of slc6a6, one 
of the most consistently, differentially expressed genes in 
our human study, resulted in a phenotype of accelerated 
glycolysis in skeletal muscle in a mouse model [36].
Fig. 6 Down-regulation of glucose levels in the media of iPSC-
derived cardiomyocytes following treatment with trastuzumab. 
Standard deviation (SD) calculated from three replicates. Time course 
of glucose concentration in the media of iPSC-derived cardiomyo-
cytes treated with trastuzumab versus untreated (control). *p = 0.04 
(72 h), p = 0.026 (96 h); **p = 0.001 (24 h), ***p < 0.0002 (48 h)
Fig. 7 Glucose and lactate levels in the media of iPSC-derived 
cardiomyocytes following 48 h treatment with trastuzumab. Standard 
deviation (SD) calculated from three replicates. Glucose levels were 
significantly higher in the media of iPSC-derived cardiomyocytes 
treated with trastuzumab relative to untreated cells, *p = 0.004. 
Levels of lactate were not significantly different between iPSC-
derived cardiomyocytes treated with trastuzumab and untreated cell, 
p = 0.329
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